Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 3/20 | 0.48 |
| ▸ | ALPI | P09923 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | SDHB | P21912 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23415014 | 0.81 | KDM4E (0.56) | ALPLALPIPKMKDM4EALDH1A1 | |
| SCHEMBL23414804 | 0.80 | ALPL (0.45) | ALPLALPIPKMKDM4EKMT2A | |
| SCHEMBL23414955 | 0.80 | ALDH1A1 (0.40) | ALPLALPIPKMKDM4EKMT2A | |
| SCHEMBL26584231 | 0.79 | PKM (0.50) | PKMKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL26120142 | 0.78 | PKM (0.49) | PKMKDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL26119458 | 0.78 | PKM (0.52) | PKMKDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL23414963 | 0.78 | KCNQ3 (0.45) | PKMKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL23414961 | 0.78 | KDM4E (0.56) | KDM4EKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23414930 | 0.76 | ALPL (0.40) | ALPLALPIPKMKDM4EKMT2A | |
| SCHEMBL17298034 | 0.75 | PKM (0.59) | PKMKDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4065579-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021108404-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | SCD5, SCD, FADS2 | ALPL 2110/4885ALPI 1543/4885PKM 1148/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | ALPL 2110/4885ALPI 1543/4885PKM 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.